"I can see you! I can see the buildings! Thank you for letting me see the light again! I'm so happy!" Recently, the Ophthalmic Medical Department of the PLA General Hospital successfully implemented miok keratoprosthesis implantation for a corneal blind patient, and the patient successfully regained vision. This is the first domestic miok keratoprosthesis implantation implemented by the Third Medical Center.
This 71 year old patient is not only blind due to Stevens Johnson syndrome, but also has cataract, diabetes and other diseases. Due to the complexity of the disease, many hospitals across the country have no results after several visits. On the recommendation of experts, the family members of the patient learned from many sources that the ophthalmology department of the Third Medical Center of the PLA General Hospital had the leading technology in treating corneal diseases in China, and immediately came to the center for treatment.
After careful examination by Professor Wang Liqiang, the deputy director of the department of ophthalmology and a well-known domestic corneal expert, it was determined that the patient was invalid for conventional corneal transplantation, and only the implementation of artificial corneal implantation could restore the patient's vision. After many discussions with Professor Huang Yifei, the director of the Academic Committee of the Department of Ophthalmology and a well-known corneal expert in China, we carefully designed an operation plan for the implantation of Mihm artificial cornea for patients. The operation was completed in two phases, and the titanium stent was implanted into the cornea with cloudy lesions in the first phase; Three months later, the secondary keratoprosthesis was performed, and the optical lens column was implanted in the center of the keratoprosthesis to play an optical role.
miok artificial cornea is an artificial cornea with independent intellectual property rights developed by our company (Beijing miok Medical Equipment Co., Ltd.). The materials used in the products are hard medical materials: titanium stent and PMMA materials, which have excellent biocompatibility, mechanical properties, low elasticity, corrosion resistance and strong processability.
Mihm artificial cornea is implanted by stages. Through intraocular perfusion and small corneal opening operation, serious intraoperative complications such as Boston artificial cornea and AlphaCor artificial cornea can be avoided to the greatest extent.
In July this year, Professor Wang Liqiang led a team of doctors to carry out a phase of artificial corneal stent implantation for patients. Recently, the patient was admitted to hospital again to complete the key step of surgery - implantation of the lens column. When the patient uncovers the gauze after surgery, the opening scene of the article appears. At that time, a ray of sunshine happened to shine into the ward, as well as into the patient's eyes and heart.
Corneal prosthesis transplantation is the only way to restore vision for patients with terminal corneal blindness, such as multiple corneal transplantation failures, severe eye burns (chemical burns, thermal burns), autoimmune correlation and cicatricial keratoconjunctival diseases. Mihm artificial cornea is made of artificial materials without donor cornea, which alleviates the shortage of corneal donors in China and provides a new way for clinical treatment of patients with contraindications of traditional corneal transplantation.
On December 7, 2021, the world's first and only artificial cornea, Mih artificial cornea, designed and developed by our company, won the Class III Medical Device Registration Certificate issued by the State Drug Administration. The acquisition of the registration certificate has opened up the "last mile" for the launch of Mihm artificial cornea.
On December 16 of the same year, our company obtained the Medical Device Production License issued by Beijing Drug Administration. Since then, miok Medical has pressed the "Fast Forward" button for the cause of blind recovery.
On November 18 this year, the Third Medical Center of the General Hospital of the People's Liberation Army carried out the first domestic MIH keratoprosthesis implantation with great success.
It is enough to prove that this is a positive signal: millions of corneal blindness patients in China are expected to see light again; The domestic artificial cornea technology with completely independent intellectual property rights has reached the world's advanced level, filling the gap in ophthalmology.
In general, Mihm keratoprosthesis has made great achievements in the field of keratoprosthesis transplantation thanks to "innovation and change", and its scientific research value is highly valued, because it is not "curve overtaking" in the process of following the research ideas of developed countries, but original scientific research achievements in the world from concept to application.
Since its establishment, miok Medical has continuously strengthened the independent innovation of the enterprise, strengthened the self-reliance of science and technology, and taken scientific and technological innovation as the top of the enterprise's development strategy, and as an important means to promote the high-quality development of the enterprise, adding a brick to the national ownership of [independent intellectual property rights of artificial cornea].
At the same time, miok Medical has always been committed to encouraging, guiding and helping blind friends to go out of their homes, integrate into the society, improve the quality of life, and truly fight for the light through scientific and technological means.